Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer - The KEYNOTE-062 Phase 3 Randomized Clinical Trial

In patients with untreated, locally advanced/unresectable or metastatic gastric cancer with PD-L1 positive score of ≥1 (n=763), pembrolizumab was non-inferior (and not superior) to chemotherapy (median overall survival of 10.6 vs 11.1 months; HR 0.91; 99.2% CI 0.69-1.18).

SPS commentary:

The study also evaluated pembrolizumab plus chemotherapy and found this was also not superior to chemotherapy alone for either overall (12.5 vs 11.1 months; HR 0.85; 95% CI, 0.70-1.03; P =0.05) or progression-free (6.9 vs 6.4 months; HR 0.84; 95% CI 0.70-1.02; P =0.04) survival.


JAMA Oncology

Resource links: